Johnson and Johnson reaches USD 700 million talc settlement with US states

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-06-12 06:00 GMT   |   Update On 2024-06-20 18:37 GMT

New York: Johnson & Johnson has reached a settlement of $700 million to resolve an investigation by 42 U.S. states and Washington, D.C. regarding its marketing of baby powder and other talc-based items linked to cancer allegations. 

The settlement resolves charges that Johnson & Johnson deceived consumers by implying that its talc products, which it had sold for over a century before the stoppage, were safe.

Advertisement
J&J did not admit wrongdoing in settling with the states, which were led by Florida, North Carolina and Texas, and has said its talc products are safe and do not cause cancer, as per a Reuters report. The company announced a settlement in principle in January.
"This is a major advancement for consumer product safety," Florida Attorney General Ashley Moody said in a statement.
J&J still faces tens of thousands of talc lawsuits, and a class action accusing the New Brunswick, New Jersey-based company of fraudulently hiding their dangers from shareholders.
As of March 31, about 61,490 people were still suing J&J over talc. Most were women with ovarian cancer, while a smaller number had mesothelioma, a type of cancer linked to asbestos.
J&J stopped selling talc-based baby powder globally last year, switching to corn starch as the main ingredient. It has maintained that its products do not contain asbestos.
The company has twice tried to resolve the litigation by placing into bankruptcy a subsidiary it created to contain its talc liabilities, but courts rebuffed both attempts.
On May 1, J&J proposed a $6.48 billion settlement to resolve most of the litigation through a third bankruptcy filing. It has set aside an $11 billion reserve to cover all talc liabilities.
"The company continues to pursue several paths to achieve a comprehensive and final resolution of the talc litigation," Erik Haas, J&J worldwide vice president of litigation, said in a statement on Tuesday.
"We will continue to address the claims of those who do not want to participate in our contemplated consensual bankruptcy resolution through litigation or settlement," he added.
Read also: JnJ Orthopaedics Company DePuy Synthes gets 510(k) FDA clearance of VELYS Robotic-Assisted Solution for use in Unicompartmental Knee Arthroplasty Procedures
Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News